Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD refers eFoodSafety to FTC

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division refers eFoodSafety.com to the Federal Trade Commission for possible law enforcement action for Internet advertising claims the firm made about its Cinnergen dietary supplement. As part of its routine monitoring program, NAD targeted Cinnergen for health-related establishment and performance claims including: "clinically proven to control blood sugar" and "over half the patients in our clinical study were able to stop taking prescribed medication!" according to a Feb. 7 decision. The Council of Better Business Bureaus group's numerous attempts to contact eFoodSafety were unsuccessful, NAD says...

You may also be interested in...



Claims Implying Supplement Could Replace Insulin Must Go, NAD Says

Implying that eFoodSafety.com's glucose-metabolism supplement Cinnergen is a replacement for normal insulin regimens is misleading, the National Advertising Division says

Holland & Barrett Pulls Irish CBD Products Following Safety Concerns

Holland & Barrett's Jacob Hooy brand is one of 15 CBD products recalled by the Irish food authority due to higher than stated doses of THC. 

BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Topics

UsernamePublicRestriction

Register

PS101346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel